ESMO 2016 | Effect of cabozantinib on quality of life in renal cell carcinoma
Sumanta Pal
Sumanta Kumar Pal, MD of City of Hope , Duarte, CA shares the new research in renal cell carcinoma he is most excited about at the European Society for Molecular Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. He discusses data he is presenting at this congress on quality of life in the context of cabozantinib treatment (NCT01865747). Dr Pal describes the step-wise increase in quality of life seen during the course of therapy with this second-line agent in renal cell carcinoma, and argues why he prefers cabozantinib over other treatment options.
Related videos
1:10
Beyond cancer treatment: nurse specialists in the clinic
Simon Crabb
4:25
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
Thomas Powles
1:55
Awaiting key results for enzalutamide and apalutamide in nmCRPC
Simon Crabb
2:04
How to involve patients in clinical decision making
Joe O'Sullivan
2:18
Not enough attention paid to bone health in prostate cancer
Simon Crabb
